BAYRY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 15:59):

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...

Stats
Today's Volume	2.49M
Average Volume	1.95M
Market Cap	27.59B
EPS	$0 ( 2024-03-05 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0.632 ( 2023-05-02 )
Next Dividend	$0 ( N/A )
P/E	-8.77
ATR14	$0.00700 (0.10%)

Volume Correlation

Long: -0.12 (neutral)

Short: -0.48 (neutral)

Signal:(42.15) Neutral

Bayer Aktiengesellschaft Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bayer Aktiengesellschaft Correlation - Currency/Commodity

-0.75
( moderate negative )

0.00
( neutral )

-0.04
( neutral )

Bayer Aktiengesellschaft Financials

Annual	2023
Revenue:	$47.64B
Gross Profit:	$27.89B (58.54 %)
EPS:	$-2.99

Q4	2023
Revenue:	$11.86B
Gross Profit:	$7.38B (62.18 %)
EPS:	$1.360

Q3	2023
Revenue:	$10.34B
Gross Profit:	$5.53B (53.47 %)
EPS:	$-4.65

Q2	2023
Revenue:	$11.04B
Gross Profit:	$6.33B (57.28 %)
EPS:	$-1.920

Financial Reports:

No articles found.

Bayer Aktiengesellschaft Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.632 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bayer Aktiengesellschaft Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.24 - low (7.78%) | Divividend Growth Potential Score: 2.39 - Decrease likely (52.25%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.320	2001-04-25
Last Dividend	$0.632	2023-05-02
Next Dividend	$0	N/A
Payout Date	2023-05-15
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$12.19	--
Avg. Dividend % Per Year	0.00%	--
Score	1.58	--
Div. Sustainability Score	3.24
Div.Growth Potential Score	2.39
Div. Directional Score	2.81	--

Next Divdend (Est)
(2025-03-31)

$0.640 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.58

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
VOPKY	Ex Dividend Knight	2023-05-03	Annually	0.00%
MCBI	Ex Dividend Junior	2023-08-04	Quarterly	0.00%
CNLTN	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
SMAL	Ex Dividend Knight	2023-08-24	Quarterly	0.00%
HENKY	Ex Dividend Knight	2023-04-25	Annually	0.00%
ASHTY	Ex Dividend Knight	2023-08-10	Semi-Annually	0.00%
NIDB	Ex Dividend Knight	2023-08-10	Bi-Monthly	0.00%
DBSDY	Ex Dividend Knight	2023-08-11	Quarterly	0.00%
TDHOF	Ex Dividend Junior	2023-09-28	Annually	0.00%
IDKOF	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0617	1.500	-1.235	-1.852	[0 - 0.5]
returnOnAssetsTTM	-0.0238	1.200	-0.795	-0.954	[0 - 0.3]
returnOnEquityTTM	-0.0816	1.500	-2.02	-3.03	[0.1 - 1]
payoutRatioTTM	-0.806	-1.000	-8.06	8.06	[0 - 1]
currentRatioTTM	1.259	0.800	8.70	6.96	[1 - 3]
quickRatioTTM	0.784	0.800	-0.0946	-0.0757	[0.8 - 2.5]
cashRatioTTM	0.201	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.355	-1.500	4.08	-6.11	[0 - 0.6]
interestCoverageTTM	0.595	1.000	-0.891	-0.891	[3 - 30]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.05	2.00	8.97	10.00	[0 - 20]
debtEquityRatioTTM	1.332	-1.500	4.67	-7.01	[0 - 2.5]
grossProfitMarginTTM	0.585	1.000	3.58	3.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0333	1.000	-1.333	-1.333	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.109	1.000	-0.507	-0.507	[0.2 - 2]
assetTurnoverTTM	0.386	0.800	-0.759	-0.607	[0.5 - 2]
Total Score				3.24

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.32	1.000	-0.335	0	[1 - 100]
returnOnEquityTTM	-0.0816	2.50	-1.297	-3.03	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.05	2.00	9.32	10.00	[0 - 30]
dividendYielPercentageTTM	9.10	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
payoutRatioTTM	-0.806	1.500	-8.06	8.06	[0 - 1]
pegRatioTTM	0.246	1.500	-1.696	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.100	1.000	10.00	0	[0.1 - 0.5]
Total Score				2.39

Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.